Concepts (255)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Teratoma | 3 | 2019 | 8 | 1.630 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2018 | 187 | 1.580 |
Why?
|
| Mouth Neoplasms | 5 | 2018 | 60 | 1.020 |
Why?
|
| Hodgkin Disease | 2 | 2018 | 13 | 0.840 |
Why?
|
| Head and Neck Neoplasms | 2 | 2019 | 81 | 0.820 |
Why?
|
| Ovarian Neoplasms | 3 | 2017 | 406 | 0.790 |
Why?
|
| Textile Industry | 1 | 2022 | 2 | 0.750 |
Why?
|
| Dust | 1 | 2022 | 55 | 0.710 |
Why?
|
| Occupational Exposure | 1 | 2022 | 89 | 0.700 |
Why?
|
| Skin | 3 | 2017 | 185 | 0.670 |
Why?
|
| Domestic Violence | 1 | 2020 | 32 | 0.660 |
Why?
|
| Neurilemmoma | 1 | 2019 | 5 | 0.620 |
Why?
|
| India | 10 | 2025 | 105 | 0.620 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2019 | 10 | 0.610 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 23 | 0.610 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2019 | 1 | 0.610 |
Why?
|
| Humans | 40 | 2025 | 42163 | 0.590 |
Why?
|
| Mycosis Fungoides | 1 | 2018 | 2 | 0.580 |
Why?
|
| Mycobacterium leprae | 2 | 2017 | 2 | 0.570 |
Why?
|
| Female | 27 | 2025 | 24018 | 0.570 |
Why?
|
| Leukoplakia, Oral | 1 | 2018 | 5 | 0.560 |
Why?
|
| Leprosy, Lepromatous | 1 | 2017 | 1 | 0.560 |
Why?
|
| Peritoneal Neoplasms | 1 | 2017 | 18 | 0.550 |
Why?
|
| Staining and Labeling | 1 | 2017 | 106 | 0.530 |
Why?
|
| Mediastinal Neoplasms | 1 | 2017 | 6 | 0.530 |
Why?
|
| Glioma | 1 | 2017 | 92 | 0.510 |
Why?
|
| Vitelline Duct | 1 | 2016 | 1 | 0.500 |
Why?
|
| Receptor, erbB-2 | 1 | 2018 | 149 | 0.500 |
Why?
|
| Umbilicus | 1 | 2016 | 4 | 0.500 |
Why?
|
| Intestinal Fistula | 1 | 2016 | 4 | 0.500 |
Why?
|
| Immunohistochemistry | 5 | 2019 | 928 | 0.500 |
Why?
|
| Ascomycota | 1 | 2016 | 21 | 0.500 |
Why?
|
| Adult | 20 | 2025 | 13458 | 0.490 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 175 | 0.490 |
Why?
|
| Exophiala | 1 | 2015 | 2 | 0.480 |
Why?
|
| Sigmoid Neoplasms | 1 | 2015 | 1 | 0.480 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2016 | 53 | 0.480 |
Why?
|
| Dermatomycoses | 1 | 2015 | 7 | 0.480 |
Why?
|
| Ovarian Cysts | 1 | 2015 | 3 | 0.480 |
Why?
|
| Myxoma | 1 | 2015 | 5 | 0.480 |
Why?
|
| Vulvar Neoplasms | 1 | 2015 | 10 | 0.480 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 233 | 0.470 |
Why?
|
| Adenoma | 1 | 2016 | 94 | 0.460 |
Why?
|
| Middle Aged | 17 | 2019 | 11819 | 0.450 |
Why?
|
| Gene Expression | 1 | 2018 | 692 | 0.440 |
Why?
|
| Pregnancy Complications | 2 | 2025 | 134 | 0.420 |
Why?
|
| Diagnosis, Differential | 7 | 2019 | 236 | 0.400 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2017 | 12 | 0.400 |
Why?
|
| Kidney | 3 | 2019 | 363 | 0.370 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 77 | 0.350 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 246 | 0.330 |
Why?
|
| Male | 19 | 2019 | 22779 | 0.330 |
Why?
|
| Splenic Artery | 1 | 2009 | 2 | 0.310 |
Why?
|
| Splenic Diseases | 1 | 2009 | 3 | 0.310 |
Why?
|
| Necrosis | 1 | 2009 | 54 | 0.310 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 1679 | 0.300 |
Why?
|
| Meckel Diverticulum | 1 | 2008 | 1 | 0.290 |
Why?
|
| Jejunal Diseases | 1 | 2008 | 2 | 0.290 |
Why?
|
| Choristoma | 1 | 2008 | 4 | 0.290 |
Why?
|
| Pancreas | 1 | 2008 | 45 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2006 | 150 | 0.280 |
Why?
|
| Ultrasonography | 2 | 2019 | 132 | 0.280 |
Why?
|
| Muscle Neoplasms | 1 | 2007 | 1 | 0.270 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2007 | 2 | 0.270 |
Why?
|
| Multicystic Dysplastic Kidney | 1 | 2007 | 1 | 0.260 |
Why?
|
| Maxillary Neoplasms | 1 | 2006 | 1 | 0.260 |
Why?
|
| Odontogenic Tumors | 1 | 2006 | 1 | 0.260 |
Why?
|
| Treatment Outcome | 4 | 2019 | 1586 | 0.260 |
Why?
|
| Maxilla | 1 | 2006 | 7 | 0.260 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 48 | 0.250 |
Why?
|
| Keratins | 2 | 2022 | 25 | 0.250 |
Why?
|
| Calcinosis | 1 | 2006 | 61 | 0.240 |
Why?
|
| Placenta Diseases | 1 | 2005 | 5 | 0.240 |
Why?
|
| Hemangioma | 1 | 2005 | 7 | 0.240 |
Why?
|
| Fibrosarcoma | 1 | 2005 | 8 | 0.240 |
Why?
|
| Chorionic Villi | 1 | 2005 | 5 | 0.240 |
Why?
|
| Infant, Newborn | 4 | 2016 | 960 | 0.240 |
Why?
|
| Stillbirth | 1 | 2025 | 20 | 0.240 |
Why?
|
| Ki-67 Antigen | 1 | 2005 | 34 | 0.230 |
Why?
|
| Abdominal Injuries | 1 | 2004 | 6 | 0.230 |
Why?
|
| Thoracic Injuries | 1 | 2004 | 12 | 0.230 |
Why?
|
| Wilms Tumor | 1 | 2004 | 4 | 0.230 |
Why?
|
| Fibroma | 1 | 2004 | 4 | 0.220 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 53 | 0.220 |
Why?
|
| Child | 5 | 2019 | 3381 | 0.220 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 228 | 0.220 |
Why?
|
| Cystic Adenomatoid Malformation of Lung, Congenital | 1 | 2004 | 2 | 0.210 |
Why?
|
| Pleural Neoplasms | 1 | 2004 | 57 | 0.210 |
Why?
|
| Young Adult | 7 | 2025 | 4936 | 0.210 |
Why?
|
| Adolescent | 7 | 2017 | 5950 | 0.200 |
Why?
|
| Epithelial Cells | 1 | 2006 | 426 | 0.200 |
Why?
|
| Entamoebiasis | 1 | 2022 | 2 | 0.200 |
Why?
|
| Child, Preschool | 4 | 2017 | 1516 | 0.200 |
Why?
|
| Prognosis | 3 | 2015 | 850 | 0.190 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2013 | 59 | 0.190 |
Why?
|
| Cotton Fiber | 1 | 2022 | 5 | 0.190 |
Why?
|
| Mucin-1 | 1 | 2022 | 11 | 0.190 |
Why?
|
| Infant | 2 | 2019 | 1143 | 0.170 |
Why?
|
| Biopsy | 2 | 2019 | 176 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2019 | 31 | 0.160 |
Why?
|
| Retrospective Studies | 3 | 2017 | 2485 | 0.150 |
Why?
|
| Abdomen | 2 | 2017 | 13 | 0.150 |
Why?
|
| Adrenal Glands | 1 | 2019 | 17 | 0.150 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2019 | 19 | 0.150 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1420 | 0.150 |
Why?
|
| Hyperpigmentation | 1 | 2018 | 10 | 0.150 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 53 | 0.150 |
Why?
|
| Histocytochemistry | 2 | 2009 | 47 | 0.140 |
Why?
|
| Breast | 1 | 2019 | 139 | 0.140 |
Why?
|
| Suppuration | 1 | 2017 | 3 | 0.140 |
Why?
|
| Histological Techniques | 1 | 2017 | 12 | 0.140 |
Why?
|
| Case-Control Studies | 3 | 2018 | 1266 | 0.140 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 602 | 0.140 |
Why?
|
| Immunoenzyme Techniques | 3 | 2006 | 111 | 0.130 |
Why?
|
| DNA, Ribosomal Spacer | 1 | 2016 | 5 | 0.130 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 13 | 0.130 |
Why?
|
| DNA, Fungal | 1 | 2016 | 47 | 0.130 |
Why?
|
| Radiography | 1 | 2016 | 72 | 0.120 |
Why?
|
| Microscopy | 1 | 2016 | 33 | 0.120 |
Why?
|
| Hand | 1 | 2016 | 33 | 0.120 |
Why?
|
| Polycystic Kidney Diseases | 2 | 2007 | 4 | 0.120 |
Why?
|
| Intestines | 1 | 2016 | 71 | 0.120 |
Why?
|
| Burns | 1 | 2015 | 10 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 577 | 0.120 |
Why?
|
| Cicatrix | 1 | 2015 | 17 | 0.120 |
Why?
|
| Pregnancy | 3 | 2025 | 1737 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 508 | 0.110 |
Why?
|
| Quality of Life | 1 | 2018 | 599 | 0.100 |
Why?
|
| Macrophages | 1 | 2017 | 515 | 0.100 |
Why?
|
| Temefos | 1 | 2013 | 1 | 0.100 |
Why?
|
| Culex | 1 | 2013 | 4 | 0.100 |
Why?
|
| Insecticide Resistance | 1 | 2013 | 14 | 0.100 |
Why?
|
| Aged | 6 | 2012 | 7982 | 0.100 |
Why?
|
| Insecticides | 1 | 2013 | 54 | 0.100 |
Why?
|
| Inflammation | 1 | 2017 | 729 | 0.090 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2012 | 22 | 0.090 |
Why?
|
| Oncogene Protein v-akt | 1 | 2011 | 20 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2006 | 727 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2012 | 84 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 180 | 0.090 |
Why?
|
| Metals, Rare Earth | 1 | 2009 | 3 | 0.080 |
Why?
|
| Barium | 1 | 2009 | 16 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2013 | 393 | 0.080 |
Why?
|
| Energy Transfer | 1 | 2009 | 32 | 0.080 |
Why?
|
| Glass | 1 | 2009 | 19 | 0.080 |
Why?
|
| Phosphates | 1 | 2009 | 54 | 0.080 |
Why?
|
| Hyaline Cartilage | 1 | 2009 | 1 | 0.080 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2009 | 3 | 0.080 |
Why?
|
| Splenectomy | 1 | 2009 | 9 | 0.080 |
Why?
|
| Aluminum | 1 | 2009 | 39 | 0.080 |
Why?
|
| DNA Mutational Analysis | 2 | 2006 | 97 | 0.080 |
Why?
|
| Eye | 1 | 2009 | 80 | 0.080 |
Why?
|
| Peritonitis | 1 | 2008 | 11 | 0.070 |
Why?
|
| Duodenal Ulcer | 1 | 2008 | 6 | 0.070 |
Why?
|
| Intestinal Perforation | 1 | 2008 | 11 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2008 | 82 | 0.070 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 83 | 0.070 |
Why?
|
| Mechlorethamine | 1 | 2007 | 1 | 0.070 |
Why?
|
| Procarbazine | 1 | 2007 | 1 | 0.070 |
Why?
|
| Dacarbazine | 1 | 2007 | 6 | 0.070 |
Why?
|
| Vinblastine | 1 | 2007 | 9 | 0.070 |
Why?
|
| Vincristine | 1 | 2007 | 14 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2007 | 23 | 0.070 |
Why?
|
| Prednisone | 1 | 2007 | 31 | 0.070 |
Why?
|
| Bleomycin | 1 | 2007 | 21 | 0.070 |
Why?
|
| Apoptosis | 2 | 2012 | 1541 | 0.070 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2007 | 22 | 0.070 |
Why?
|
| Maxillary Sinus | 1 | 2006 | 4 | 0.060 |
Why?
|
| Mesoderm | 1 | 2007 | 73 | 0.060 |
Why?
|
| Orbit | 1 | 2006 | 11 | 0.060 |
Why?
|
| Epithelium | 1 | 2007 | 78 | 0.060 |
Why?
|
| Leprosy, Borderline | 1 | 2006 | 1 | 0.060 |
Why?
|
| Leprosy, Tuberculoid | 1 | 2006 | 1 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 59 | 0.060 |
Why?
|
| Rare Diseases | 1 | 2006 | 17 | 0.060 |
Why?
|
| S100 Proteins | 1 | 2006 | 13 | 0.060 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2006 | 12 | 0.060 |
Why?
|
| Peripheral Nerves | 1 | 2006 | 14 | 0.060 |
Why?
|
| Neurosurgical Procedures | 1 | 2006 | 27 | 0.060 |
Why?
|
| Genes, ras | 1 | 2006 | 25 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2007 | 95 | 0.060 |
Why?
|
| Vimentin | 1 | 2006 | 38 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 92 | 0.060 |
Why?
|
| Arm | 1 | 2005 | 28 | 0.060 |
Why?
|
| Sentinel Surveillance | 1 | 2025 | 24 | 0.060 |
Why?
|
| Actins | 1 | 2006 | 162 | 0.060 |
Why?
|
| Cytodiagnosis | 1 | 2005 | 10 | 0.060 |
Why?
|
| Wounds, Stab | 1 | 2004 | 5 | 0.060 |
Why?
|
| Thoracotomy | 1 | 2004 | 5 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2006 | 1574 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 209 | 0.060 |
Why?
|
| Multiple Trauma | 1 | 2004 | 8 | 0.060 |
Why?
|
| Smoking | 1 | 2012 | 1019 | 0.060 |
Why?
|
| Genes, BRCA2 | 1 | 2004 | 12 | 0.060 |
Why?
|
| Genes, BRCA1 | 1 | 2004 | 20 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 454 | 0.060 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2004 | 31 | 0.060 |
Why?
|
| Genes, p53 | 1 | 2004 | 28 | 0.060 |
Why?
|
| Prenatal Care | 1 | 2025 | 82 | 0.060 |
Why?
|
| Neoplastic Processes | 1 | 2004 | 2 | 0.050 |
Why?
|
| Wounds, Gunshot | 1 | 2004 | 30 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2004 | 74 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2012 | 2803 | 0.050 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2004 | 40 | 0.050 |
Why?
|
| Lymphangioma | 1 | 2003 | 5 | 0.050 |
Why?
|
| Intestinal Neoplasms | 1 | 2003 | 6 | 0.050 |
Why?
|
| Hamartoma | 1 | 2003 | 6 | 0.050 |
Why?
|
| Mesothelioma | 1 | 2004 | 148 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2005 | 733 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2003 | 51 | 0.050 |
Why?
|
| Diarrhea | 1 | 2022 | 95 | 0.050 |
Why?
|
| Feces | 1 | 2022 | 126 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 190 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 1051 | 0.040 |
Why?
|
| Lung | 1 | 2004 | 484 | 0.040 |
Why?
|
| Bacteria | 1 | 2022 | 285 | 0.040 |
Why?
|
| Dermatitis, Contact | 1 | 2018 | 2 | 0.040 |
Why?
|
| Prurigo | 1 | 2018 | 2 | 0.040 |
Why?
|
| Lichen Planus | 1 | 2018 | 5 | 0.040 |
Why?
|
| Amyloidosis | 1 | 2018 | 38 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 61 | 0.030 |
Why?
|
| Disease Vectors | 1 | 2013 | 11 | 0.020 |
Why?
|
| Biological Assay | 1 | 2013 | 63 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2012 | 138 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 362 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 236 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 534 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 462 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 587 | 0.020 |
Why?
|
| Neodymium | 1 | 2009 | 3 | 0.020 |
Why?
|
| Ytterbium | 1 | 2009 | 2 | 0.020 |
Why?
|
| Erbium | 1 | 2009 | 3 | 0.020 |
Why?
|
| Absorption | 1 | 2009 | 22 | 0.020 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2009 | 32 | 0.020 |
Why?
|
| Optical Phenomena | 1 | 2009 | 18 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 21 | 0.020 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2009 | 21 | 0.020 |
Why?
|
| Safety | 1 | 2009 | 51 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2012 | 534 | 0.020 |
Why?
|
| Antitubercular Agents | 1 | 2009 | 33 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2009 | 184 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 845 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 1139 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 973 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 1008 | 0.020 |
Why?
|
| Epithelioid Cells | 1 | 2006 | 1 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2006 | 30 | 0.020 |
Why?
|
| Granuloma | 1 | 2006 | 24 | 0.020 |
Why?
|
| Time Factors | 1 | 2009 | 1848 | 0.010 |
Why?
|
| Pedigree | 1 | 2004 | 94 | 0.010 |
Why?
|
| Mesentery | 1 | 2003 | 9 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 3942 | 0.010 |
Why?
|
| Pelvis | 1 | 2003 | 15 | 0.010 |
Why?
|
| Prevalence | 1 | 2004 | 1597 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 16695 | 0.010 |
Why?
|